Retatrutide

FDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition, and that it cannot lawfully be used in compounding. Promising trial results do not make research-market retatrutide an approved medicine.^[2]

Jurisdiction

United States

Product

Retatrutide-containing products

Indication

No FDA-approved indication in the cited communication

Record date

2026-09-08

• Jurisdiction and status are tied to the agency communication accessed by the cutoff; the page's own stated currency date is 2026-09-01.

By September 2026, ClinicalTrials.gov listed multiple Eli Lilly-sponsored phase 3 retatrutide trials as completed or active, including a completed obesity-and-cardiovascular-disease trial (TRIUMPH-3, 1,946 participants), alongside a separately registered pre-approval single-patient expanded-access protocol for severe, treatment-refractory obesity. No approved US product containing retatrutide was identified as of the cutoff.^[3][4][2]

Jurisdiction

United States

Product

Retatrutide (LY3437943), investigational

Indication

No FDA-approved indication; phase 3 obesity/cardiovascular trials and a pre-approval expanded-access protocol were registered

Record date

2026-09-08

• A registry sweep of 34 retatrutide records was screened for phase/status/sponsor only; it does not summarize trial results, and expanded access is a single-patient compassionate-use mechanism, not a step toward guaranteed approval.

In a 48-week phase 2 obesity trial, the highest retatrutide dose group had mean weight loss of 24.2% versus 2.1% with placebo. Gastrointestinal events and dose-related heart-rate increases were reported.^[1]

• Investigational trial findings are not a personalized outcome or a head-to-head comparison with another treatment.
• Only the published abstract was inspected; no PMC full text exists for this article, so full methods, tables and supplementary appendices were not reviewed.

A Bayesian network meta-analysis published in 2025 pooled 19 randomized controlled trials covering 29,506 adults with a body-mass index of 25 kg/m2 or more, comparing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide and placebo at 36 weeks or later. Its abstract reports that retatrutide and the dual agonists produced equivalent mean weight loss of 11.0 kg, more than the GLP-1 receptor agonists at 9.0 kg, and that for reaching at least 15% weight loss the odds ratios were 54.6 for retatrutide, 16.4 for the dual agonists and 9.0 for the GLP-1 receptor agonists. It also reports that retatrutide carried the highest risk of adverse events, and that in meta-regression the presence of type 2 diabetes was associated with less weight loss. These are indirect comparisons across trials, not head-to-head results.^[5]

• Abstract-only inspection. The included-trial list, risk-of-bias assessment, network structure and heterogeneity statistics were not read, because no lawful full-text copy was reachable.
• The abstract does not name the 19 pooled trials or state their development phase, so this record cannot show which trial of any compound contributed to which estimate. The survodutide and retatrutide results recorded elsewhere in this reference come from phase 2 dose-finding trials, the same records also list completed phase 3 trials of both compounds, and semaglutide and tirzepatide are approved for weight management, so the pooled classes may combine evidence of unequal maturity.
• A network meta-analysis estimates comparisons between treatments that were mostly never tested against each other. Its rankings are model outputs, not measured differences.
• The GLP-1 receptor agonists and the dual agonists are pooled by class in the reported results, so the abstract gives no separate estimate for semaglutide, survodutide or tirzepatide; retatrutide is reported on its own because the abstract treats it as a group of one.
• The meta-regression associations are observational comparisons across trials, not randomized ones.
• This finding is recorded as cross-compound context. It is not evidence about any single compound's own trial results, which are recorded separately on each record.